玻璃体切除术联合玻璃体腔内注射康柏西普治疗增生性糖尿病视网膜病变患者的效果OA

Objective:To explore the effect of vitrectomy combined with intravitreal injection of Conbercept in the treatment of proliferative diabetic retinopathy.Method:A total of 76 patients with proliferative diabetic retinopathy admitted to the Affiliated Eye Hospital of Nanjing Medical University from October 2022 to October 2023 were retrospectively selected.The patients were divided into control group and observation group,38 cases in each group.The control group was given vitrectomy,and the observation group was given vitrectomy combined with intravitreal injection of Conbercept.The recovery,serum factors,quality of life and safety of the two groups were compared.Result:Three months after operation,the best corrected visual acuity(BCVA),intraocular pressure and macular central retinal thickness(CRT)in observation group were lower than those in control group,the differences were statistically significant(P＜0.05).Three months after operation,the levels of vascular endothelial growth factor(VEGF)and placental growth factor(PIGF)in observation group were lower than those in control group,the differences were statistically significant(P＜0.05).Three months after operation,the Chinese version of low vision quality of life scale(CLVQOL)score in the observation group was higher than that in the control group,and the difference was statistically significant(P＜0.05).The incidence of complications in the observation group was lower than that in the control group,the difference was statistically significant(P＜0.05).Conclusion:Intravitreous injection of Conbercept before vitrectomy has a significant effect in patients with proliferative diabetic retinopathy,which can reduce intraocular pressure,reduce retinal thickness,regulate serum factors,improve vision,and have certain safety and quality of life.